ライフサイエンスコーパス: gene delivery system

1 ar polyethylenimine (PEI)-containing in vivo gene delivery system.

2 as it identifies osteoclasts as an ideal CD gene delivery system.

3 erived from lentiviruses provide a promising gene delivery system.

4 ted this effect using an adenovirus-mediated gene delivery system.

5 Plasmids may have unique advantages as a gene delivery system.

6 position, size and multifunctionality of the gene-delivery system.

7 use lungs, superior to several gold standard gene delivery systems.

8 ween toxicity and transfection efficiency in gene delivery systems.

9 a new transfection multiplier for non-viral gene delivery systems.

10 ns in nanoelectronics, sensing, and drug and gene delivery systems.

11 s on the development of efficient, non-toxic gene delivery systems.

12 ic, efficient, tumor cell- specific systemic gene delivery systems.

13 fficiency of G100R Env would be an asset for gene delivery systems.

14 ach should be useful for the design of other gene delivery systems.

15 systemically delivered nanoparticle nonviral gene delivery systems.

16 ducers and analyzed entirely using transient gene delivery systems.

17 e livers using the in situ DNA injection and gene delivery systems.

18 lethanolamine are highly effective non-viral gene delivery systems.

19 the rational design of optimal peptide-based gene delivery systems.

20 a promising new class of synthetic nonviral gene delivery systems.

21 ed with DNA plasmids to create peptide-based gene delivery systems.

22 ons, ranging from nanostructures to nonviral gene delivery systems.

23 e availability of in vivo cell-type-specific gene delivery systems.

24 ies in the development of safe and efficient gene-delivery systems.

25 n that of commonly used cationic lipid-based gene-delivery systems.

26 ene expression in polycation-based, nonviral gene delivery systems, a number of CQ analogues with var

27 seases, is currently hampered by the lack of gene delivery systems able to cross the blood-brain barr

28 In contrast to other gene delivery systems, adeno-associated virus vectors sh

29 biodistribution and metabolism of non-viral gene delivery systems administered systemically are dire

30 to be successful, the development of proper gene delivery systems and hypoxia-regulated gene express

31 Thus, gene therapy using a retrovirus-based gene delivery system appears to be a feasible approach t

32 y for health care will not be realized until gene delivery systems are capable of achieving efficient

33 Non-viral gene delivery systems are one of the most potential alte

34 We previously reported a gene delivery system based on a fiber gene-deleted Ad ty

35 The availability of a stable gene delivery system based on a multiply attenuated lent

36 We formulated a new gene delivery system based on targeted liposomes.

37 herapy, and allow for the development of new gene delivery systems based on in vitro-generated papill

38 Here we present a non-viral gene-delivery system based on multisegment bimetallic na

39 AVs) have attracted considerable interest as gene delivery systems because they show long-term expres

40 lular and intracellular limitations of other gene delivery systems by binding reversibly and condensi

41 demonstrates that the Agrobacterium-mediated gene delivery system can be used to study the cis- and t

42 ansposon system is a highly active non-viral gene delivery system capable of integrating defined DNA

43 The single-plasmid gene delivery system carries both the piggyBac transposa

44 rexpression of caveolin-1, via an adenoviral gene delivery system, clearly accelerated endothelial ce

45 requires systemic delivery systems, a novel gene delivery system composed of liposome/protamine/DNA

46 The combined hRK and AAV gene delivery system could be an effective gene therapy

47 the subject of intense research as non-viral gene delivery systems, due to their flexible properties,

48 racterization of different nanosized drug or gene delivery systems, e.g., polymers, nanoparticles, mi

49 ested in developing a noninvasive cell-based gene delivery system for the CNS that exploits the natur

50 The goal of this study was to develop a gene delivery system for the prolonged and controlled re

51 Adaptation of in vitro optimized polymeric gene delivery systems for in vivo use remains a signific

52 n made to exploit cardioprotective drugs and gene delivery systems for myocardial infarction (MI).

53 Retroviral gene delivery systems for RNA polymerase II (RNA pol II)

54 The development of gene delivery systems for therapeutic use involves vecto

55 ine and suggest the potency of a local IL-22 gene-delivery system for treating UC.

56 utility of the adeno-associated virus (AAV) gene delivery system has been validated by the regulator

57 The adeno-associated virus (AAV) vector gene delivery system has shown promise in several clinic

58 s have been prepared, and their potential as gene delivery systems has been evaluated in comparison w

59 Both viral and nonviral vector gene delivery systems have been used to target specific

60 Non-viral gene delivery systems have the potential to create viabl

61 r gene, using an in vivo adenoviral mediated gene delivery system in a murine model.

62 irus (MLV) is currently the most widely used gene delivery system in gene therapy trials.

63 apeutic effectiveness of this erythropoietin gene delivery system in vitro.

64 -mediated and cationic liposome-mediated E1A gene delivery systems in an orthotopic breast cancer ani

65 posomal, PEI, dendrimer, stem cell and viral gene delivery systems in order to determine the techniqu

66 t prevalent in current nonviral polycationic gene-delivery systems in which the polycationic nature o

67 Variations in gene delivery systems, including virus-type and latency

68 transduction by using an HIV-1-based vector gene delivery system into various human cell types inclu

69 To determine its utility as a gene delivery system, it was important to assess the epi

70 ith the RIPtk gene, delivered by a liposomal gene delivery system, maintained their blood glucose lev

71 Cytotoxic gene-delivery systems may compromise these processes and

72 Synthetic nanoparticle-based gene delivery systems offer highly tunable platforms for

73 execution of inhaled gene therapy, including gene delivery systems, primary physiological barriers an

74 Self-assembled synthetic gene delivery systems represent the bottom-up approach t

75 ormone gene formulated in an optimal peptide gene delivery system show an increase in gene expression

76 for breast cancer, consisting of a nonviral gene delivery system (SN) and a proapoptotic gene, bik.

77 ent of fusion resulted in a highly efficient gene delivery system specific for liver cells in culture

78 Compared with viral vectors, synthetic gene-delivery systems, such as liposomes and polymers, o

79 The demonstration of an efficient gene delivery system targeted specifically to SMCs provi

80 a novel simian virus (SV) 40-derived vector gene delivery system that efficiently transduces human l

81 We have constructed a recombinant adenovirus gene delivery system that is capable of undergoing growt

82 r a preclinical proof-of-concept for a novel gene delivery system that offers an effective intratrach

83 We have developed a gene delivery system that utilizes a cell-binding helper

84 ry and balance function is likely to require gene delivery systems that target auditory and vestibula

85 ovirions (HPV-PsVs) approach is an effective gene-delivery system that can prime or boost an immune r

86 eve to be a novel microinjection-based local gene-delivery system that is capable of targeting the in

87 a plasmid DNA using polyethylenimine as the gene delivery system, thereby circumventing the problem

88 In contrast to other viral gene delivery systems, this minimally invasive procedure

89 ciently, we employed an inducible adenoviral gene delivery system to achieve tightly controlled expre

90 lineage cells could function as a cell-based gene delivery system to bone cancers.

91 oward that end, we constructed an adenovirus gene delivery system to enable robust, glial-specific, a

92 yocytopoiesis, we used a lentiviral-mediated gene delivery system to prevent physiologic down-regulat

93 ropylenimine dendrimer is a highly promising gene delivery system to the brain.

94 show that adv is a highly efficient in vivo gene delivery system to treat experimental human melanom

95 We have now used two gene delivery systems to target TGF alpha overexpression

96 These data confirm that this EPO gene delivery system using a bioreducible polymeric carr

97 We developed an efficient T-DNA-based gene delivery system using Agrobacterium tumefaciens to

98 Although the development of gene delivery systems via non-viral-mediated methods is

99 A polymeric gene delivery system was developed to deliver the solubl

100 A polymeric gene delivery system was developed to deliver the solubl

101 transduction efficacy of a lentivirus based gene delivery system was not augmented.

102 The gene delivery system was tested in healthy rodents and p

103 An in vivo adenoviral gene delivery system was utilized to assess the effect o

104 adenovirus-mediated gene transfer as a model gene delivery system, we cloned the peptide SIGYPLP and

105 terize the use of baculovirus as a mammalian gene delivery system, we examined the status of transduc

106 To address the need for more efficient gene delivery systems, we have developed replication-com

107 e problem of creating nontoxic but effective gene-delivery systems, we hypothesized that by optimizin

108 The peptide-based gene delivery systems were tested for transfection effic

109 stimuli triggered, photothermal controllable gene delivery system, which can be further applied to ma

110 may also aid in the development of nonviral gene delivery systems with increased efficiency.

111 In contrast, gene delivery systems with RNA pol III-based expression

112 rane-particle interactions in the context of gene delivery systems, with the aim to guide the design